Galectin Therapeutics Inc. 2016 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2016, filed March 28, 2017. Galectin Therapeutics is a clinical-stage biopharmaceutical company with no approved products or commercial revenue. Its primary candidate, GR-MD-02, targets galectin proteins, particularly galectin-3, for fibrotic disease, cancer immunotherapy and severe skin disease.
- Primary program: Phase 2b NASH-CX trial in patients with NASH cirrhosis.
- NASH-CX enrollment was completed in September 2016 with 162 patients at 36 U.S. sites; top-line data was expected in December 2017.
- NASH-FX, a 30-patient Phase 2a trial in advanced fibrosis without cirrhosis, did not meet its primary or secondary biomarker endpoints, although GR-MD-02 was reported safe and well tolerated.
- Additional investigator-sponsored Phase 1b studies evaluated GR-MD-02 with ipilimumab and pembrolizumab in cancer. The pembrolizumab study reported one partial response and one mixed response among five melanoma patients in the initial cohort.
Financial performance and liquidity
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $15.325 million | $13.114 million | +17% |
| General and administrative expense | $6.156 million | $6.965 million | -12% |
| Total operating expenses | $21.481 million | $20.079 million | +7% |
| Net loss | $21.436 million | $20.027 million | +7% |
| Net loss applicable to common stockholders | $22.350 million | $21.124 million | +6% |
| Basic and diluted loss per share | $0.76 | $0.88 | Loss per share improved |
| Net cash used in operations | $16.409 million | $16.983 million | Use decreased $0.574 million |
| Cash and cash equivalents at year-end | $15.362 million | $25.846 million | Down $10.484 million |
R&D increased primarily because of Phase 2 clinical-trial costs, while preclinical spending declined. G&A decreased mainly because of lower stock-based compensation, accounting and travel costs, partially offset by higher legal expenses. No meaningful revenue, gross margin or profitability metrics exist because the company remains pre-revenue.
The balance sheet reported total assets of $15.795 million, total liabilities of $3.780 million and stockholders’ equity of $10.292 million. Management stated that the company had no debt-related market exposure and the filing reports no material borrowed debt. Contractual obligations consisted primarily of approximately $41,000 of operating-lease payments due in 2017.
Material changes versus the prior comparable period
- R&D spending increased $2.211 million as the NASH-CX Phase 2 program advanced and enrollment was completed.
- Operating cash use declined modestly, but year-end cash fell by $10.484 million because financing proceeds were insufficient to offset operating expenditures.
- Financing proceeds decreased to $5.925 million from $13.701 million in 2015. 2016 financing included $2.508 million from Series B-3 preferred stock, $3.000 million from private placements of common stock and warrants, and $416,000 from at-the-market common-stock sales.
- Series B-1 and B-2 preferred stock was reclassified from redeemable preferred stock to permanent equity after the redemption feature was eliminated.
- Outstanding warrants increased to 13.488 million from 8.909 million, creating substantial potential dilution.
- Common shares outstanding increased to 32.913 million at December 31, 2016 from 28.825 million at December 31, 2015.
Guidance, outlook, risks and unusual items
- Management believed available cash, together with subsequent financing, would fund currently planned operations through December 31, 2017, but stated that additional capital would be required thereafter.
- From January 1 through March 1, 2017, the company raised $1.247 million through its at-the-market program. On February 28, 2017, it raised an additional $200,000 in a private placement and issued warrants for 76,776 common shares at $5.00 per share.
- Management warned that failure to obtain additional financing could require significant reductions in operations or cessation of operations. Future equity financing could materially dilute existing holders.
- Clinical development remains highly uncertain. NASH-FX failed to meet its endpoints, and success of the larger NASH-CX trial is not assured.
- All product candidates require FDA and foreign regulatory approval; none had been approved for commercial sale as of the filing.
- The company relies heavily on third parties for clinical research, manufacturing and potential commercialization and has no internal commercial manufacturing or sales infrastructure.
- Shareholder class-action and derivative litigation remained subject to appeals. The company stated that it could not estimate potential losses, although it did not believe reasonably possible losses were material based on available information.
- NASDAQ listing risk was significant: the stock traded below the $1.00 minimum bid price for 26 consecutive trading days during October-November 2016.
- The 10X Fund and related parties held substantial conversion, warrant, voting and approval rights, potentially affecting financing, governance and change-of-control decisions.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2016.
Most important facts for investors to verify
- Actual top-line and full results from the NASH-CX Phase 2b trial, including the HVPG primary endpoint and safety findings.
- Cash burn, financing availability and the timing and terms of capital raises needed after 2017.
- Potential dilution from 13.488 million warrants, 4.657 million options and preferred-stock conversion rights.
- Regulatory pathway, clinical-trial requirements and the probability of advancing GR-MD-02 to Phase 3 and eventual approval.
- Status and potential financial exposure of the remaining shareholder litigation and appeals.
- Compliance with NASDAQ continued-listing requirements and any reverse-split or other capital-structure actions.